COMP <GO>

CNSP vs UPC // FORWARD P/E MULTIPLE

CNS Pharmaceuticals Inc. (NASDAQ) VS. Universe Pharmaceuticals Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: CNSP 1 — UPC 2

■ METRIC PARITY

LAST: $5.00 (+4.82%) • MKT CAP: $7.3M

forward-pe

—

LAST: $1.49 (-3.25%) • MKT CAP: $7.5M

forward-pe

—

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CNSP VS. UPC) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	CNSP	UPC	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	35.30%	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-35.00%	—	—	TIE	/roic <GO>
EV/EBITDA & P/E Valuation	—	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	—	—	—	TIE	/fcf-yield <GO>
Operating Margin	—	-16.30%	—	TIE	/operating-margins <GO>
Net Profit Margin	—	-20.60%	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	-22.40%	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	—	—	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	1/9	2/9	-1.00	UPC	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	49.3	22.9	+26.40	CNSP	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple ACTIVE	—	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$7.3M	$7.5M	-$179.1K	UPC	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	CNSP REV	UPC REV	CNSP GROSS %	UPC GROSS %	CNSP FCF	UPC FCF
FY 2025	$0	$17.86B	—	35.3%	-$13.8M	-$5.32B
FY 2024	$0	$23.02B	—	26.4%	-$17.1M	-$9.72B
FY 2023	$0	$32.31B	—	—	-$14.1M	$1.12B

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

CNSP // BETA —

UPC // BETA —